Len Reyno

Company: C4 Therapeutics

Job title: Chief Medical Officer

Seminars:

Initial Clinical Data From the Ongoing Clinical Trial of CFT1946 8:30 am

NEW DATA Well-tolerated at all dose levels; no dose-limiting toxicities Dose proportional pharmacokinetic exposure; successfully degrades BRAF V600 mutant protein Early evidence of CFT1946 monotherapy anti-tumor activity in patients who have progressed on or after BRAF inhibitor therapies Preclinical data demonstrating blood-brain barrier permeabilityRead more

day: Day Two AM